MooreMD, PostmaE, GrayKD, UllmannTM, HurleyJR, GoldsmithS, SobelVR, SchulmanA, ScognamiglioT, ChritosPJ, HassettE, LuickJ, WhitehallD, ZarnegarR, FaheyTJ. 2018. Less is more: the impact of Multidisciplinary Thyroid Conference on the treatment of well-differentiated thyroid carcinoma. World J Surg, 42:343–349.
2.
NixonIJ, GanlyI, PatelSG, PalmerFL, Di LorenzoMM, GrewalRK, LarsonSM, TuttleRM, ShahaA, ShahJP. 2013. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid, 23:683–694.
3.
TuttleRM, AlzahraniAS. 2019. Risk stratification in differentiated thyroid cancer: from detection to final follow-up. J Clin Endocrinol Metab, 104:4087–4100.
4.
BoucaiL, FalconeJ, UkenaJ, CoombsCC, ZehirA, PtashkinR, BergerMF, LevineRL, FaginJA. 2018. Radioactive iodine-related clonal hematopoiesis in thyroid cancer is common and associated with decreased survival. J Clin Endocrinol Metab, 103:4216–4223.
5.
SingerMC, MarchalF, AngelosP, BernetV, BoucaiL, BuchholzerS, BurkeyB, EiseleD, ErkulE, FaureF, FreitagSK, GillespieMB, HarrellRM, HartlD, HaymartM, LeffertJ, MandelS, MillerBS, MorrisJ, PearceEN, RahmatiR, RyanWR, SchaitkinB, SchlumbergerM, StackBC, Van NostrandD, WongKK, RandolphG. 2020. Salivary and lacrimal dysfunction after radioactive iodine for differentiated thyroid cancer: American Head and Neck Society Endocrine Surgery Section and Salivary Gland Section joint multidisciplinary clinical consensus statement of otolaryngology, ophthalmology, nuclear medicine and endocrinology. Head Neck, 42:3446–3459.
6.
YaishI, AzemF, GutfeldO, SilmanZ, SerebroM, SharonO, SheferG, LimorR, SternN, TordjmanKM. 2018. A single radioactive iodine treatment has a deleterious effect on ovarian reserve in women with thyroid cancer: results of a Prospective Pilot Study. Thyroid, 28:522–527.
7.
BourcigauxN, RubinoC, BerthaudI, ToubertME, DonadilleB, LeenhardtL, Petrot-KellerI, Brailly-TabardS, FromigueJ, de VathaireF, SimonT, SiffroiJP, SchlumbergerM, BouchardP, Christin-MaitreS. 2018. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma. Hum Reprod, 33:1408–1416.
8.
YuCY, SaeedO, GoldbergAS, FarooqS, FazelzadR, GoldsteinDP, TsangRW, BrierleyJD, EzzatS, ThabaneL, GoldsmithCH, SawkaAM. 2018. A systematic review and meta-analysis of subsequent malignant neoplasm risk after radioactive iodine treatment of thyroid cancer. Thyroid, 28:1662–1673.
9.
MolenaarRJ, PleyerC, RadivoyevitchT, SidanaS, GodleyA, AdvaniAS, GerdsAT, CarrawayHE, KalaycioM, NazhaA, AdelsteinDJ, NasrC, AngeliniD, MaciejewskiJP, MajhailN, SekeresMA, MukherjeeS. 2018. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia, 32:952–959.
10.
MendozaA, ShafferB, KaraklaD, MasonME, ElkinsD, GoffmanTE. 2004. Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. Thyroid, 14:133–140.
CaglarM, TuncelM, AlparR. 2002. Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med, 27:767–771.
13.
KloosRT, DuvuuriV, JhiangSM, CahillKV, FosterJA, BurnsJA. 2002. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. J Clin Endocrinol Metab, 87:5817–5820.
14.
MorgensternKE, VadysirisackDD, ZhangZ, CahillKV, FosterJA, BurnsJA, KloosRT, JhiangSM. 2005. Expression of sodium iodide symporter in the lacrimal drainage system: implication for the mechanism underlying nasolacrimal duct obstruction in I(131)-treated patients. Ophthalmic Plast Reconstr Surg, 21:337–344.
AliMJ, VyakaranamAR, RaoJE, PrasadG, ReddyPV. 2017. Iodine-131 therapy and lacrimal drainage system toxicity: nasal localization studies using whole body nuclear scintigraphy and SPECT-CT. Ophthalmic Plast Reconstr Surg, 33:13–16.
17.
JonklaasJ. 2014. Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction. Thyroid, 24:1806–1814.
18.
LeeJY, WooKI. 2022. Surgical risk prediction for nasolacrimal duct obstruction in radioactive iodine-treated thyroid cancer: a Nationwide Cohort Study. Thyroid [Epub ahead of print]; DOI: 10.1089/thy.2021.0418
19.
Diamond-RossiSA, JonklaasJ, JensenRE, KuoC, StearnsS, EspositoG, DavidsonBJ, LutaG, BloomG, GravesKD. 2020. Looking under the hood of “the Cadillac of cancers:” radioactive iodine-related craniofacial side effects among patients with thyroid cancer. J Cancer Surviv, 14:847–857.
20.
LubitzCC, KiernanCM, ToumiA, ZhanT, RothMY, SosaJA, TuttleRM, GrubbsEG. 2021. Patient perspectives on the extent of surgery and radioactive iodine treatment for low-risk differentiated thyroid cancer. Endocr Pract, 27:383–389.
21.
GoswamiS, MongelliM, PeipertBJ, HelenowskiI, YountSE, SturgeonC. 2018. Benchmarking health-related quality of life in thyroid cancer versus other cancers and United States normative data. Surgery, 164:986–992.
22.
RothEM, LubitzCC, SwanJS, JamesBC. 2020. Patient-reported quality-of-life outcome measures in the thyroid cancer population. Thyroid, 30:1414–1431.
23.
MolsF, SchoormansD, SmitJWA, Netea-MaierRT, LinksTP, van der GraafWTA, HussonO. 2018. Age-related differences in health-related quality of life among thyroid cancer survivors compared with a normative sample: results from the PROFILES Registry. Head Neck, 40:2235–2245.
24.
ApplewhiteMK, JamesBC, KaplanSP, AngelosP, KaplanEL, GroganRH, Aschebrook-KilfoyB. 2016. Quality of life in thyroid cancer is similar to that of other cancers with worse survival. World J Surg, 40:551–561.
25.
GoswamiS, PeipertBJ, MongelliMN, KurumetySK, HelenowskiIB, YountSE, SturgeonC. 2019. Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors. Surgery, 166:69–74.
